Read Larry Connors' blog – Short Term Trading Strategies
"Canine influenza is a highly contagious respiratory infection that has a significant impact on dogs housed in shelters, kennels and communal facilities," said Cynda Crawford, D.V.M., Ph.D., University of Florida, Clinical Assistant Professor of Shelter Medicine. "The availability of a vaccine can help prevent the medical, financial and emotional costs associated with this new virus."
Canine influenza was first identified in the United States in 2004. Since then, CIV has continued to spread and has now been detected in dogs in 30 states and the District of Columbia, according to Dr. Crawford and Edward J. Dubovi, Ph.D., Professor of Virology, Cornell University College of Veterinary Medicine, two of the nation's leading experts on Canine H3N8 who have been tracking the disease since 2004.
Most dogs have no immunity to canine influenza because it is a novel pathogen and, therefore, the infection can spread quickly through animal shelters, adoption groups, pet stores, boarding kennels, veterinary clinics and any location where dogs congregate. According to the U.S. Centers for Disease Control and Prevention (CDC), there is no evidence of transmission of the virus from dogs to people.
According to Terri Wasmoen, Ph.D., an immunologist and senior director of Biological Research for Intervet/Schering-Plough Animal Health, dog owners might not realize their pets are sick enough to need medical care until the dogs begin coughing, which occurs several days or more after the dog contracts CIV. The onset of coughing is a sign that the dog is vulnerable to pneumonia. "Preventing a viral infection that can make dogs susceptible to a complex of canine respiratory pathogens, commonly known as kennel cough syndrome, further strengthens the case for vaccination," she said.
In 2006, the American Veterinary Medical Association (AVMA) called for the development of a vaccine against the spread of the disease, stating "there is urgent need for an effective canine influenza vaccine to improve the health and welfare of animals and reduce the financial impacts of canine influenza."
Christopher Pappas, Jr., D.V.M., Director, Companion Animal Technical Services, Intervet/Schering-Plough Animal Health, said, "We developed the vaccine in response to the growing problem of the disease. We are pleased that our expertise in respiratory disease and vaccines can help prevent costly outbreaks and keep dogs healthier."
Canine Influenza Vaccine, H3N8 has been demonstrated to reduce the incidence and severity of lung lesions, as well as the duration of coughing and viral shedding. The vaccine, made from inactivated virus, is intended as an aid in the control of disease associated with canine influenza virus infection, a type A, subtype H3N8. It is administered by subcutaneous injection in two doses, two to four weeks apart. It may be given to dogs six weeks of age or older and can be given annually as a component of existing respiratory disease vaccine protocols to ensure more comprehensive protection.
On May 27, 2009, the vaccine was granted a conditional license by the USDA's Animal and Plant Health Inspection Service, which, through its Center for Veterinary Biologics (CVB), evaluates data supporting product purity, product safety under normal conditions of use in field safety trials and demonstration that the product has a reasonable expectation of efficacy. During the conditional license period, Intervet/Schering-Plough Animal Health will continue to submit data obtained in support of the product's performance, which will be evaluated by government regulators to determine whether a regular product license may be issued.
About Intervet/Schering-Plough Animal Health
Intervet/Schering-Plough Animal Health is a leader in research and dedicated to the development, production and marketing of innovative, high-quality animal-health products for all major farm and companion animal species. For more information about Intervet/Schering-Plough Animal Health visit: www.intervet.com and www.intervetusa.com.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, New Jersey, USA, and its website is www.schering-plough.com."
SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the private Securities Litigation Reform Act of 1995, including statements related to expectations or forecasts of future events.
Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A "Risk Factors" in the Company's first quarter 2009 10-Q, filed May 1, 2009.
SOURCE Intervet/Schering-Plough Animal Health
http://www.intervet.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
